Sinopharm Subsidiary Sinopharm Accord Reports Q3 Revenue Decline
Sinopharm Group Co. Ltd. reported that its subsidiary, China National Accord Medicines Corporation Ltd. (Sinopharm Accord), experienced a revenue decline of 1.89% year-on-year, totaling RMB 18.33 billion for Q3 2025. However, total assets increased by 6.31% to RMB 50.56 billion, and equity attributable to shareholders rose by 4.30% to RMB 18.43 billion compared to the previous year.
Sinopharm Group Co. Ltd. announced key unaudited financial data for its subsidiary, China National Accord Medicines Corporation Ltd. (Sinopharm Accord), for the third quarter of 2025. Sinopharm Accord reported revenue of RMB 18.33 billion for the quarter, a 1.89% decrease year-on-year. Total assets at the end of the reporting period reached RMB 50.56 billion, up 6.31% from the end of last year. Equity attributable to shareholders stood at RMB 18.43 billion, reflecting a 4.30% increase compared to the end of last year. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Sinopharm Group Co. Ltd. published the original content used to generate this news brief on October 30, 2025, and is solely responsible for the information contained therein. © Copyright 2025 - Public Technologies (PUBT) Original Document: here
